Company intelligence
As of November 8, 2026, T-Therapeutics has raised at least $133M in equity across 1 sourced funding round.
Is something wrong on this page?
| Date | Round | Amount | Valuation | Lead investors | Source |
|---|---|---|---|---|---|
| Nov 8, 2026 | Series B | $133M | — | British Business Bankunverified WithM Ventures (Merck KGaA)unverifiedEli Lilly and CompanyunverifiedSofinnova PartnersunverifiedF-Prime CapitalunverifiedDigitalis VenturesunverifiedSanofi VenturesunverifiedTencentunverifiedAdvent Life SciencesJohnson & Johnson InnovationSamsara BioCapitalCambridge Innovation Capital+1 more | Pulse 2.0 |
Equity only. “Equity raised” above sums the rounds with a dated, linked source; rumored rounds, tender offers and secondary sales are listed but not counted, and debt financing is listed separately.
T-Therapeutics has raised at least $133M in equity across 1 sourced funding round tracked by Value Add VC. The most recent was a $133M Series B in November 2026, reported by Pulse 2.0. Debt financing, tender offers and secondary sales are not counted.
Lead investors in T-Therapeutics's sourced funding rounds include British Business Bank. Per round: its November 2026 Series B was led by British Business Bank.
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.